- Home
- DVA vs QGEN Comparison
DVA vs QGEN Comparison
Compare DVA & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DVA
- QGEN
- Stock Information
- Founded
- DVA 1994
- QGEN 1986
- Country
- DVA United States
- QGEN Netherlands
- Employees
- DVA N/A
- QGEN N/A
- Industry
- DVA Misc Health and Biotechnology Services
- QGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DVA Health Care
- QGEN Health Care
- Exchange
- DVA Nasdaq
- QGEN Nasdaq
- Market Cap
- DVA 9.4B
- QGEN 10.7B
- IPO Year
- DVA 1995
- QGEN 1996
- Fundamental
- Price
- DVA $119.80
- QGEN $44.40
- Analyst Decision
- DVA Hold
- QGEN Buy
- Analyst Count
- DVA 4
- QGEN 7
- Target Price
- DVA $145.00
- QGEN $50.68
- AVG Volume (30 Days)
- DVA 957.9K
- QGEN 1.2M
- Earning Date
- DVA 10-29-2025
- QGEN 11-04-2025
- Dividend Yield
- DVA N/A
- QGEN 3.41%
- EPS Growth
- DVA 5.63
- QGEN 331.20
- EPS
- DVA 9.76
- QGEN 1.84
- Revenue
- DVA $13,317,965,000.00
- QGEN $2,070,781,000.00
- Revenue This Year
- DVA $6.24
- QGEN $7.37
- Revenue Next Year
- DVA $3.32
- QGEN $5.65
- P/E Ratio
- DVA $12.45
- QGEN $24.10
- Revenue Growth
- DVA 5.14
- QGEN 5.32
- 52 Week Low
- DVA $115.39
- QGEN $37.63
- 52 Week High
- DVA $179.60
- QGEN $51.88
- Technical
- Relative Strength Index (RSI)
- DVA 38.97
- QGEN 40.63
- Support Level
- DVA $118.75
- QGEN $42.82
- Resistance Level
- DVA $125.68
- QGEN $45.36
- Average True Range (ATR)
- DVA 3.56
- QGEN 1.08
- MACD
- DVA 0.10
- QGEN -0.12
- Stochastic Oscillator
- DVA 27.51
- QGEN 31.60
About DVA DaVita Inc.
DaVita is the largest provider of dialysis services in the United States, boasting market share of about 35% when measured by clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 280,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business. Berkshire Hathaway owns about 45% of DaVita.
About QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).